Article(id=1326652873959650059, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1326652873431167754, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2025.02.001, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1730995200000, receivedDateStr=2024-11-08, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794228293169, onlineDateStr=2026-11-09, pubDate=1739116800000, pubDateStr=2025-02-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794228293169, onlineIssueDateStr=2026-11-09, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794228293169, creator=13701087609, updateTime=1794228293169, updator=13701087609, issue=Issue{id=1326652873431167754, tenantId=1146029695717560320, journalId=1319690329412173987, year='2025', volume='46', issue='2', pageStart='107', pageEnd='210', issueExtLink='null', onlineDate='null', pubDate='1739116800000', pubDateStr='2025-02-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794228293043, creator='13701087609', updateTime=1794273094848, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1326840786227934185, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1326652873431167754, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1326840786227934186, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1326652873431167754, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=107, endPage=122, ext={EN=ArticleExt(id=1326652874202919693, articleId=1326652873959650059, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Progress in the clinical application of targeted therapy for intermediate and advanced non-small cell lung cancer, columnId=1326652874119033612, journalTitle=World Clinical Drug, columnName=Recommendation, runingTitle=null, highlight=null, articleAbstract=
The clinical use of targeted agents has revolutionized treatment strategies for non-small cell lung cancer(NSCLC) patients carrying targetable mutations for two decades, and has resulted in significant survival benefits. In recent years, the types and clinical use of targeted agents have expanded, with breakthroughs in the treatment of advanced to locally advanced unresectable patients and perioperative adjuvant treatment of resectable patients. In advanced patients, the combination of targeted drugs with chemotherapy or dual-antibody drugs has also provided new options for first-line and subsequent treatment. Meanwhile, antibody-drug conjugates have made positive progress in the subsequent treatment of advanced patients. This article aimed to review the research progress of targeted drugs in the clinical application of intermediate and advanced NSCLC.
, authors=Hongbo LI, Ying YANG, Yongfeng YU, Shun LU
*, authorsList=Hongbo LI, Ying YANG, Yongfeng YU, Shun LU, authorCompany=null, correspAuthors=Shun LU, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1326652874622350095, articleId=1326652873959650059, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=中晚期非小细胞肺癌靶向治疗药物临床应用进展, columnId=1326652874295194382, journalTitle=世界临床药物, columnName=本期推荐, runingTitle=null, highlight=null, articleAbstract=
靶向药物的临床应用在近20年来革新了携带可药用基因突变非小细胞肺癌患者的治疗策略,并带来显著生存获益。近年来,靶向药物的种类及临床应用不断扩展,在晚期至局部晚期不可切除患者的治疗,以及可切除患者围手术期治疗的应用均取得突破性成果。在晚期患者中,靶向药物与化疗或双抗类药物的联合治疗方案也为一线治疗及后线治疗提供新方案。同时,抗体偶联药物在晚期患者的后线治疗中取得积极进展。文章综述了靶向药物在中晚期非小细胞肺癌临床应用的研究进展。
, authors=李泓伯, 杨莹, 虞永峰, 陆舜
*, authorsList=李泓伯, 杨莹, 虞永峰, 陆舜, authorCompany=null, correspAuthors=陆舜, authorNote=
, correspAuthorsNote=
陆舜,主任医师,研究方向:肺癌的靶向治疗与免疫治疗。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=mlGC/W1G4mkhUNoV10XLfA==, magXml=nSQ4b/GaQTg1zqUbubVsrQ==, pdfUrl=null, pdf=6P9gSOLEUZOqmmHVMXPJmw==, pdfFileSize=1454335, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=/6Z3V+jztbYdr7d7B9Avog==, mapNumber=null, fund=null)}, authors=[Author(id=1326652874966283028, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652875033391894, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, authorId=1326652874966283028, language=EN, stringName=Hongbo LI, firstName=Hongbo, middleName=null, lastName=LI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652875108889367, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, authorId=1326652874966283028, language=CN, stringName=李泓伯, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=上海交通大学医学院附属胸科医院肿瘤科,上海 200030, bio={"content":"
李泓伯,博士研究生,研究方向:肿瘤内科。
"}, bioImg=null, bioContent=
李泓伯,博士研究生,研究方向:肿瘤内科。
, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652874844648208, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, xref=null, ext=[AuthorCompanyExt(id=1326652874853036817, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, companyId=1326652874844648208, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China), AuthorCompanyExt(id=1326652874865619730, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, companyId=1326652874844648208, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=上海交通大学医学院附属胸科医院肿瘤科,上海 200030)])]), Author(id=1326652876761445146, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652876836942620, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, authorId=1326652876761445146, language=EN, stringName=Ying YANG, firstName=Ying, middleName=null, lastName=YANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652876895662877, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, authorId=1326652876761445146, language=CN, stringName=杨莹, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=上海交通大学医学院附属胸科医院肿瘤科,上海 200030, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652874844648208, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, xref=null, ext=[AuthorCompanyExt(id=1326652874853036817, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, companyId=1326652874844648208, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China), AuthorCompanyExt(id=1326652874865619730, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, companyId=1326652874844648208, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=上海交通大学医学院附属胸科医院肿瘤科,上海 200030)])]), Author(id=1326652876958577439, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652877042463521, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, authorId=1326652876958577439, language=EN, stringName=Yongfeng YU, firstName=Yongfeng, middleName=null, lastName=YU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652877109572386, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, authorId=1326652876958577439, language=CN, stringName=虞永峰, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=上海交通大学医学院附属胸科医院肿瘤科,上海 200030, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652874844648208, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, xref=null, ext=[AuthorCompanyExt(id=1326652874853036817, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, companyId=1326652874844648208, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China), AuthorCompanyExt(id=1326652874865619730, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, companyId=1326652874844648208, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=上海交通大学医学院附属胸科医院肿瘤科,上海 200030)])]), Author(id=1326652877168292644, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1326652877252178726, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, authorId=1326652877168292644, language=EN, stringName=Shun LU, firstName=Shun, middleName=null, lastName=LU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
*, address=Department of Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652877315093287, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, authorId=1326652877168292644, language=CN, stringName=陆舜, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
*, address=上海交通大学医学院附属胸科医院肿瘤科,上海 200030, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652874844648208, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, xref=null, ext=[AuthorCompanyExt(id=1326652874853036817, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, companyId=1326652874844648208, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China), AuthorCompanyExt(id=1326652874865619730, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, companyId=1326652874844648208, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=上海交通大学医学院附属胸科医院肿瘤科,上海 200030)])])], keywords=[Keyword(id=1326652877428339496, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, language=EN, orderNo=1, keyword=targeted therapy), Keyword(id=1326652877537391401, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, language=EN, orderNo=2, keyword=lung cancer), Keyword(id=1326652877596111658, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, language=EN, orderNo=3, keyword=non-small cell lung cancer), Keyword(id=1326652877667414827, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, language=CN, orderNo=1, keyword=靶向治疗), Keyword(id=1326652877726135084, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, language=CN, orderNo=2, keyword=肺癌), Keyword(id=1326652877789049645, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, language=CN, orderNo=3, keyword=非小细胞肺癌)], refs=[Reference(id=1326652878015542063, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=BRAY F, LAVERSANNE M, SUNG H,
et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263., articleTitle=null, refAbstract=null), Reference(id=1326652878082650928, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=WANG SY, LONG H, LI N,
et al. Adjuvant icotinib of 12 months or 6 months versus observation following adjuvant chemotherapy for resected
EGFR-mutated stageⅡ-Ⅲa non-small-cell lung cancer(ICTAN, GASTO1002): a randomized phase 3 trial[J]. J Clin Oncol, 2024, 42(16 suppl): 8004., articleTitle=null, refAbstract=null), Reference(id=1326652878149759793, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=HERBST RS, WU YL, JOHN T,
et al. Adjuvant osimertinib for resected
EGFR-mutated stageⅠb -Ⅲa non-small-cell lung cancer: updated results from the phase Ⅲ randomized ADAURA trial[J]. J Clin Oncol, 2023, 41(10): 1830-1840., articleTitle=null, refAbstract=null), Reference(id=1326652878221062962, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=TSUBOI M, HERBST RS, JOHN T,
et al. Overall survival with osimertinib in resected
EGFR-mutated NSCLC[J]. N Engl J Med, 2023, 389(2): 137-147., articleTitle=null, refAbstract=null), Reference(id=1326652878288171827, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=WU YL, DZIADZIUSZKO R, AHN JS,
et al. Alectinib in resected
ALK-positive non-small-cell lung cancer[J]. N Engl J Med, 2024, 390(14): 1265-1276., articleTitle=null, refAbstract=null), Reference(id=1326652878351086388, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=ANTONIA SJ, VILLEGAS A, DANIEL D,
et al. Durvalumab after chemoradiotherapy in stageⅢ non-small-cell lung cancer[J]. N Engl J Med, 2017, 377(20): 1919-1929., articleTitle=null, refAbstract=null), Reference(id=1326652878409806645, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHOU Q, CHEN M, JIANG O,
et al. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage Ⅲ non-small-cell lung cancer in China(GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial[J]. Lancet Oncol, 2022, 23(2): 209-219., articleTitle=null, refAbstract=null), Reference(id=1326652878481109814, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=MOK TS, WU YL, THONGPRASERT S,
et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J]. N Engl J Med, 2009, 361(10): 947-957., articleTitle=null, refAbstract=null), Reference(id=1326652878556607287, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHOU CC, WU YL, CHEN GY,
et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer(OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study[J]. Lancet Oncol, 2011,12(8): 735-742., articleTitle=null, refAbstract=null), Reference(id=1326652878611133240, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=SORIA JC, OHE Y, VANSTEENKISTE J,
et al. Osimertinib in untreated
EGFR-mutated advanced non-small-cell lung cancer[J]. N Engl J Med, 2018, 378(2): 113-125., articleTitle=null, refAbstract=null), Reference(id=1326652878682436409, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=XING LG, WU G, WANG LH,
et al. Erlotinib versus etoposide/cisplatin with radiation therapy in unresectable stage Ⅲ epidermal growth factor receptor mutation-positive non-small cell lung cancer: a multicenter, randomized, open-label, phase 2 trial[J]. Int J Radiat Oncol Biol Phys, 2021,109(5): 1349-1358., articleTitle=null, refAbstract=null), Reference(id=1326652878745350970, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=HOTTA K, SAEKI S, YAMAGUCHI M,
et al. Gefitinib induction followed by chemoradiotherapy in
EGFR-mutant, locally advanced non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase Ⅱ study[J]. ESMO Open, 2021, 6(4):100191., articleTitle=null, refAbstract=null), Reference(id=1326652878812459835, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=LU S, KATO T, DONG XR,
et al. Osimertinib after chemoradiotherapy in stage Ⅲ
EGFR-mutated NSCLC[J].N Engl J Med, 2024, 391(7): 585-597., articleTitle=null, refAbstract=null), Reference(id=1326652878875374396, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=ClinicalTrials.gov. A phaseⅢ, randomised, double-blind, placebo-controlled, multi-centre study of almonertinib as maintenance therapy in patients with locally advanced, unresectable
EGFR mutation-positive non-small cell lung cancer(stageⅢ) who have not progressed following definitive, platinum-based chemoradiation therapy[EB/OL]. [2024-08-20]. https://clinicaltrials.gov/study/NCT04951635., articleTitle=null, refAbstract=null), Reference(id=1326652878946677565, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=CHOI J, LEE JE, CHOI CM,
et al. A phase Ⅱ, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable,
EGFR mutation-positive non-small cell lung cancer(stageⅢ) who have not progressed following definitive, platinum-based, chemoradiation therapy(PLATINUM trial)[J]. Thorac Cancer, 2022, 13(23): 3431-3435., articleTitle=null, refAbstract=null), Reference(id=1326652879026369342, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHU LC, ZOU CL, ZHANG ZC,
et al. Thoracic radiotherapy and concurrent almonertinib for unresectable stage Ⅲ
EGFR-mutated non-small-cell lung cancer: a phase 2 study[J]. Bio Med Central Cancer, 2021, 21(1): 511., articleTitle=null, refAbstract=null), Reference(id=1326652879106061119, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=ClinicalTrials.gov. Effectiveness and safety of dynamic MRD guiding treatment after aumolertinib induction therapy of
EGFR-mutation-positive unresectable stage Ⅲ non-small cell lung cancer in the MDT diagnostic model: an open-label, multicenter, randomized, phase Ⅲ study[EB/OL]. [2024-08-20]. https://clinicaltrials.gov/study/NCT04841811., articleTitle=null, refAbstract=null), Reference(id=1326652879202530112, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=ClinicalTrials.gov. A single arm, prospective, open clinical study of combination of almonertinib and concurrent chemoradiotherapy in unresectable stage Ⅲ NSCLC With
EGFR mutation[EB/OL]. [2024-08-20]. https://clinicaltrials.gov/study/NCT04952168., articleTitle=null, refAbstract=null), Reference(id=1326652879269638977, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=ETTINGER DS, WOOD DE, AISNER DL,
et al. NCCN Guidelines
® Insights: non-small cell lung cancer, version 2.2023[J]. J Natl Compr Canc Netw, 2023, 21(4): 340-350., articleTitle=null, refAbstract=null), Reference(id=1326652879332553538, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=YU HA, ARCILA ME, REKHTMAN N,
et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with
EGFR-mutant lung cancers[J]. Clin Cancer Res, 2013, 19(8): 2240-2247., articleTitle=null, refAbstract=null), Reference(id=1326652879408051011, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=LU S, DONG XR, JIAN H,
et al. AENEAS: A randomized phaseⅢ trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastaticnon-small-cell lung cancer with
EGFR exon 19 deletion or L858R mutations[J]. J Clin Oncol, 2022, 40(27): 3162-3171., articleTitle=null, refAbstract=null), Reference(id=1326652879483548484, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=SHI YK, CHEN GY, WANG X,
et al. Furmonertinib(AST2818)versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic
EGFR mutation-positive non-small-cell lung cancer(FURLONG):a multicentre, double-blind, randomised phase 3 study[J]. Lancet Respir Med, 2022, 10(11): 1019-1028., articleTitle=null, refAbstract=null), Reference(id=1326652879571628869, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=LU S, ZHOU JY, JIAN H,
et al. Befotertinib(D-0316)versus icotinib as first-line therapy for patients with
EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study[J]. Lancet Respir Med, 2023, 11(10): 905-915., articleTitle=null, refAbstract=null), Reference(id=1326652881224184646, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=CHO BC, AHN MJ, KANG JH,
et al. Lazertinib versus gefitinib as first-line treatment in patients with
EGFR-mutated advanced non-small-cell lung cancer: results from LASER301[J]. J Clin Oncol, 2023, 41(26): 4208-4217., articleTitle=null, refAbstract=null), Reference(id=1326652881291293511, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=WU SM, WANG K, CANG SD,
et al. Efficacy and safety of rezivertinib(BPI-7711) in patients with locally advanced or metastatic/recurrent
EGFR T790M-mutated NSCLC: a phase Ⅱb, multicenter, single-arm, open-label study[J]. J Clin Oncol, 2022, 40(16 suppl): 9098., articleTitle=null, refAbstract=null), Reference(id=1326652881350013768, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=XIONG AW, REN SX, LIU HM,
et al. Efficacy and safety of SH-1028 in patients with
EGFR T790M-positive NSCLC:a multicenter, single-arm, open-label, phase 2 trial[J]. J Thorac Oncol, 2022, 17(10): 1216-1226., articleTitle=null, refAbstract=null), Reference(id=1326652881408734025, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=YANG Z, TAM KY. Combination strategies using EGFR-TKI in NSCLC therapy: learning from the gap between pre-clinical results and clinical outcomes[J]. Int J Biol Sci, 2018, 14(2): 204-216., articleTitle=null, refAbstract=null), Reference(id=1326652881513591626, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=HOSOMI Y, MORITA S, SUGAWARA S,
et al. Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor:NEJ009 study[J]. J Clin Oncol, 2020, 38(2): 115-123., articleTitle=null, refAbstract=null), Reference(id=1326652881576506187, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=SAITO R, SUGAWARA S, KO R,
et al. Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated
EGFR-mutated advanced non-squamous non-small cell lung cancer: the OPAL study[J]. Eur J Cancer, 2023, 185: 83-93., articleTitle=null, refAbstract=null), Reference(id=1326652881660392268, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=PLANCHARD D, JANNE PA, CHENG Y,
et al. Osimertinib with or without chemotherapy in
EGFR-mutated advanced NSCLC[J]. N Engl J Med, 2023, 389(21): 1935-1948., articleTitle=null, refAbstract=null), Reference(id=1326652881719112525, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=JANNE PA, PLANCHARD D, KOBAYASHI K,
et al. CNS Efficacy of osimertinib with or without chemotherapy in epidermal growth factor receptor-mutated advanced non-small-cell lung cancer[J]. J Clin Oncol, 2024, 42(7): 808-820., articleTitle=null, refAbstract=null), Reference(id=1326652881786221390, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=JANNE PA, KOBAYASHI K, ROBICHAUX J,
et al. Abstract CT017: FLAURA2: Exploratory analysis of baseline(BL) and on-treatment plasma EGFRm dynamics in patients(PTS) with EGFRm advanced NSCLC treated with first-line(1L) osimertinib(OSI) ± platinum-pemetrexed[J]. Cancer Res, 2024, 84(7 supplement):CT017., articleTitle=null, refAbstract=null), Reference(id=1326652881849135951, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=KANDA S, NIHO S, KURATA T,
et al. A phaseⅢ study comparing EGFR tyrosine kinase inhibitor(EGFR-TKI)monotherapy and EGFR-TKI with inserted cisplatin(CDDP)plus pemetrexed(PEM) as a first-line treatment in patients(PTS) with advanced non-squamous non-small-cell lung cancer(NSqNSCLC) harboring
EGFR activating mutation(EGFR-NSqNSCLC): JCOG1404/WJOG8214L, AGAIN study[J]. J Clini Oncol, 2023, 41(17 suppl): LBA9009., articleTitle=null, refAbstract=null), Reference(id=1326652881903661904, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=RAMALINGAM SS, CHENG Y, ZHOU C,
et al. Mechanisms of acquired resistance to first-line osimertinib:preliminary data from the phase Ⅲ FLAURA study[J]. Ann Oncol, 2018, 29: 740., articleTitle=null, refAbstract=null), Reference(id=1326652882025296721, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=LIAM CK, AHMAD AR, HSIA TC,
et al. Randomized trial of tepotinib plus gefitinib versus chemotherapy in
EGFR-mutant NSCLC with EGFR inhibitor resistance due to MET amplification: INSIGHT final analysis[J]. Clin Cancer Res, 2023, 29(10): 1879-1886., articleTitle=null, refAbstract=null), Reference(id=1326652882109182802, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=CHO BC, KIM DW, SPIRA AI,
et al. Amivantamab plus lazertinib in osimertinib-relapsed
EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial[J]. Nat Med, 2023, 29(10): 2577-2585., articleTitle=null, refAbstract=null), Reference(id=1326652882176291667, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=CHO BC, LU S, FELIP E,
et al. Amivantamab plus lazertinib in previously untreated
EGFR-mutated advanced NSCLC[J]. N Engl J Med, 2024, 391(16): 1486-1498., articleTitle=null, refAbstract=null), Reference(id=1326652882243400532, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=PASSARO A, WANG J, WANG Y,
et al. Amivantamab plus chemotherapy with and without lazertinib in
EGFR-mutant advanced NSCLC after disease progression on osimertinib:primary results from the phaseⅢ MARIPOSA-2 study[J]. Ann Oncol, 2024, 35(1): 77-90., articleTitle=null, refAbstract=null), Reference(id=1326652882306315093, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=LEIGHL NB, AKAMATSU H, LIM SM,
et al. Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory
EGFR-mutated, advanced non-small cell lung cancer(NSCLC): Primary results, including overall survival(OS), from the global, phase 3, randomized controlled PALOMA-3 trial[J]. J Clin Oncol, 2024, 42(17 suppl): LBA8505., articleTitle=null, refAbstract=null), Reference(id=1326652882369229654, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=ELAMIN YY, NAGASAKA M, SHUM E,
et al. BLU-945 monotherapy and in combination with osimertinib(OSI)in previously treated patients with advanced
EGFR-mutant(EGFRm) NSCLC in the phase 1/2 SYMPHONY study[J]. J Clin Oncol, 2023, 41(16 suppl): 9011., articleTitle=null, refAbstract=null), Reference(id=1326652882432144215, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=SPIRA AI, SPIGEL DR, CAMIDGE DR,
et al. A phase 1/2 study of the highly selective EGFR inhibitor, BLU-701, in patients with
EGFR-mutant non-small cell lung cancer(NSCLC)[J]. J Clin Oncol, 2022, 40(16 suppl):TPS9142, articleTitle=null, refAbstract=null), Reference(id=1326652882490864472, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=ClinicalTrials.gov. A phase Ⅰ, open-label, multicenter, dose escalation and expansion study to evaluate the tolerance and pharmacokinetics of TQB3804 in subjects with advanced malignant tumors[EB/OL]. [2024-08-20]. https://clinicaltrials.gov/study/NCT04128085., articleTitle=null, refAbstract=null), Reference(id=1326652882566361945, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[43], rfOrder=42, authorNames=null, journalName=null, refType=null, unstructuredReference=ClinicalTrials.gov. A phase 1/2, open-label study to assess the safety, tolerability, pharmacokinetics, and anti-tumor activity of BBT-176 in patients with advanced non-small cell lung cancer(NSCLC) who progressed following prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI) agent[EB/OL]. [2024-08-20]. https://clinicaltrials.gov/study/NCT04820023., articleTitle=null, refAbstract=null), Reference(id=1326652882629276506, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[44], rfOrder=43, authorNames=null, journalName=null, refType=null, unstructuredReference=ROBICHAUX JP, ELAMIN YY, TAN Z,
et al. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer[J]. Nat Med, 2018, 24(5): 638-646., articleTitle=null, refAbstract=null), Reference(id=1326652882750911323, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[45], rfOrder=44, authorNames=null, journalName=null, refType=null, unstructuredReference=ROBICHAUX JP, LE XN, VIJAYAN RSK,
et al. Structure-based classification predicts drug response in
EGFR-mutant NSCLC[J]. Nature, 2021, 597(7878): 732-737., articleTitle=null, refAbstract=null), Reference(id=1326652882818020188, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[46], rfOrder=45, authorNames=null, journalName=null, refType=null, unstructuredReference=CHON K, LARKINS E, CHATTERJEE S,
et al. FDA approval summary: Amivantamab for the treatment of patients with non-small cell lung cancer with
EGFR exon 20 insertion mutations[J]. Clin Cancer Res, 2023, 29(17):3262-3266., articleTitle=null, refAbstract=null), Reference(id=1326652882876740445, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[47], rfOrder=46, authorNames=null, journalName=null, refType=null, unstructuredReference=WANG MZ, FAN Y, SUN ML,
et al. Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and
EGFR exon 20 insertion mutation(WU-KONG6): single-arm, open-label, multicentre, phase 2 trial[J]. Lancet Respir Med, 2024,12(3): 217-224., articleTitle=null, refAbstract=null), Reference(id=1326652882943849310, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[48], rfOrder=47, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHOU CC, TANG KJ, CHO BC,
et al. Amivantamab plus chemotherapy in NSCLC with
EGFR exon 20 insertions[J].N Engl J Med, 2023, 389(22): 2039-2051., articleTitle=null, refAbstract=null), Reference(id=1326652883002569567, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[49], rfOrder=48, authorNames=null, journalName=null, refType=null, unstructuredReference=KOBAYASHI Y, MITSUDOMI T. Not all epidermal growth factor receptor mutations in lung cancer are created equal:perspectives for individualized treatment strategy[J]. Cancer Sci, 2016, 107(9): 1179-1186., articleTitle=null, refAbstract=null), Reference(id=1326652883065484128, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[50], rfOrder=49, authorNames=null, journalName=null, refType=null, unstructuredReference=YANG JCH, SEQUIST LV, GEATER SL,
et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon
EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6[J]. Lancet Oncol, 2015, 16(7): 830-838., articleTitle=null, refAbstract=null), Reference(id=1326652883132592993, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[51], rfOrder=50, authorNames=null, journalName=null, refType=null, unstructuredReference=MIURA S, TANAKA H, MISUMI T,
et al. Afatinib versus chemotherapy for treatment-naive non-small cell lung cancer with a sensitizing uncommon epidermal growth factor receptor mutation: a phase Ⅲ study(ACHILLES/TORG1834)[J]. Ann Oncol, 2023, 34: S1310-S1311., articleTitle=null, refAbstract=null), Reference(id=1326652883191313250, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[52], rfOrder=51, authorNames=null, journalName=null, refType=null, unstructuredReference=WU FY, ZHOU F, ZHAO FY,
et al. A phase 2a study evaluating the efficacy and safety of sutetinib in patients with advanced non-small-cell lung cancer(NSCLC)harboring uncommon
EGFR mutations[J]. J Clin Oncol, 2023, 41(16 suppl): 9131., articleTitle=null, refAbstract=null), Reference(id=1326652883258422115, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[53], rfOrder=52, authorNames=null, journalName=null, refType=null, unstructuredReference=CHO BC, WANG YS, FELIP E,
et al. Amivantamab plus lazertinib in atypical
EGFR-mutated advanced non-small cell lung cancer(NSCLC): results from CHRYSALIS-2[J].J Clin Oncol, 2024, 42(16 suppl): 8516., articleTitle=null, refAbstract=null), Reference(id=1326652883321336676, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[54], rfOrder=53, authorNames=null, journalName=null, refType=null, unstructuredReference=GOU LY, WU YL. Prevalence of driver mutations in non-small-cell lung cancers in the People's Republic of China[J]. Lung Cancer(Auckl), 2014, 5: 1-9., articleTitle=null, refAbstract=null), Reference(id=1326652883384251237, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[55], rfOrder=54, authorNames=null, journalName=null, refType=null, unstructuredReference=PETERS S, CAMIDGE DR, SHAW AT,
et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer[J]. N Engl J Med, 2017, 377(9): 829-838., articleTitle=null, refAbstract=null), Reference(id=1326652883468137318, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[56], rfOrder=55, authorNames=null, journalName=null, refType=null, unstructuredReference=SORIA JC, TAN DSW, CHIARI R,
et al. First-line ceritinib versus platinum-based chemotherapy in advanced
ALK-rearranged non-small-cell lung cancer(ASCEND-4): a randomised, open-label, phase 3 study[J]. Lancet, 2017,389(10072): 917-929., articleTitle=null, refAbstract=null), Reference(id=1326652883535246183, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[57], rfOrder=56, authorNames=null, journalName=null, refType=null, unstructuredReference=CAMIDGE DR, KIM HR, AHN MJ,
et al. Brigatinib versus crizotinib in advanced ALK inhibitor-naive ALK-positive non-small cell lung cancer: second interim analysis of the phaseⅢ ALTA-1L trial[J]. J Clin Oncol, 2020, 38(31):3592-3603., articleTitle=null, refAbstract=null), Reference(id=1326652883593966440, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[58], rfOrder=57, authorNames=null, journalName=null, refType=null, unstructuredReference=HORN L, WANG ZP, WU G,
et al. Ensartinib
vs crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer: a randomized clinical trial[J]. J Am Med Assoc Oncol, 2021, 7(11): 1617-1625., articleTitle=null, refAbstract=null), Reference(id=1326652883648492393, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[59], rfOrder=58, authorNames=null, journalName=null, refType=null, unstructuredReference=SHI YK, CHEN JH, YANG RX,
et al. Iruplinalkib(WX-0593) versus crizotinib in ALK TKI-naive locally advanced or metastatic ALK-positive NSCLC:interim analysis of a randomized, open-label, phase 3 study(INSPIRE)[J]. J Thorac Oncol, 2024, 19(6): 912-927., articleTitle=null, refAbstract=null), Reference(id=1326652883719795562, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[60], rfOrder=59, authorNames=null, journalName=null, refType=null, unstructuredReference=YANG YP, MIN J, YANG N,
et al. Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase Ⅲtrial[J]. Signal Transduct Target Ther, 2023, 8(1): 301., articleTitle=null, refAbstract=null), Reference(id=1326652883791098731, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[61], rfOrder=60, authorNames=null, journalName=null, refType=null, unstructuredReference=SOLOMON BJ, LIU G, FELIP E,
et al. Lorlatinib
vs crizotinib in treatment-naïve patients with advanced ALK+non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study[J]. J Clin Oncol, 2024,42(17 suppl): LBA8503., articleTitle=null, refAbstract=null), Reference(id=1326652883845624684, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[62], rfOrder=61, authorNames=null, journalName=null, refType=null, unstructuredReference=LIN JJ, JOHNSON M, FELIP E,
et al. Abstract B154: Safety and preliminary activity of the selective ALK inhibitor NVL-655 in patients with ALK fusion-positive solid tumors[J]. Mol Cancer Ther, 2023, 22(12 supplement): B154., articleTitle=null, refAbstract=null), Reference(id=1326652883908539245, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[63], rfOrder=62, authorNames=null, journalName=null, refType=null, unstructuredReference=URAS IZ, MOLL HP, CASANOVA E. Targeting
KRAS mutant non-small-cell lung cancer: past, present and future[J]. Int J Mol Sci, 2020, 21(12): 4325., articleTitle=null, refAbstract=null), Reference(id=1326652883967259502, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[64], rfOrder=63, authorNames=null, journalName=null, refType=null, unstructuredReference=DE LANGEN AJ, JOHNSON ML, MAZIERES J,
et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with
KRASG12C mutation: a randomised, open-label, phase 3 trial[J]. Lancet, 2023, 401(10378):733-746., articleTitle=null, refAbstract=null), Reference(id=1326652884034368367, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[65], rfOrder=64, authorNames=null, journalName=null, refType=null, unstructuredReference=MOK TSK, YAO WX, DURUISSEAUX M,
et al. KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer(NSCLC) harboring a
KRASG12C mutation[J]. J Clin Oncol, 2024, 42(17 suppl): LBA8509., articleTitle=null, refAbstract=null), Reference(id=1326652885703701361, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[66], rfOrder=65, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHOU Q, MENG XJ, SUN LH,
et al. Efficacy and safety of KRAS G12C inhibitor IBI351 monotherapy in patients with advanced non-small cell lung cancer: results from a phase 2 pivotal study[J]. J Thorac Oncol, 2024, 19(12): 1630-1639., articleTitle=null, refAbstract=null), Reference(id=1326652885783393138, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[67], rfOrder=66, authorNames=null, journalName=null, refType=null, unstructuredReference=LI ZM, DANG XM, HUANG DZ,
et al. Garsorasib in patients with
KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial[J]. Lancet Respir Med, 2024, 12(8): 589-598., articleTitle=null, refAbstract=null), Reference(id=1326652885846307699, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[68], rfOrder=67, authorNames=null, journalName=null, refType=null, unstructuredReference=LI BT, CLARKE JM, FELIP E,
et al. Sotorasib plus carboplatin and pemetrexed in KRAS G12C advanced NSCLC: updated analysis from the international CodeBreaK 101 trial[J]. J Clin Oncol, 2024, 42(16 suppl): 8512., articleTitle=null, refAbstract=null), Reference(id=1326652885905027956, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[69], rfOrder=68, authorNames=null, journalName=null, refType=null, unstructuredReference=GARASSINO MC, THEELEN WSME, JOTTE R,
et al. LBA65 KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-native, advanced non-small cell lung cancer(NSCLC) harboring a
KRASG12C mutation[J]. Ann Oncol, 2023, 34(supplement 2): S1309-S1310., articleTitle=null, refAbstract=null), Reference(id=1326652886001496949, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[70], rfOrder=69, authorNames=null, journalName=null, refType=null, unstructuredReference=SONG ZB, LI XY, LIN RB,
et al. Safety and efficacy of ifebemtinib(IN10018) combined with D-1553 in non-small-cell lung cancer(NSCLC) with
KRASG12C mutation:results from a phaseⅠb/Ⅱ study[J]. J Clin Oncol, 2024,42(16 suppl): 8605., articleTitle=null, refAbstract=null), Reference(id=1326652886110548854, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[71], rfOrder=70, authorNames=null, journalName=null, refType=null, unstructuredReference=GREGORC V, GONZALEZ-CAO M, SALVAGNI S,
et al. KROCUS: A phaseⅡ study investigating the efficacy and safety of fulzerasib(GFH925) in combination with cetuximab in patients with previously untreated advanced
KRASG12C mutated NSCLC[J]. J Clin Oncol, 2024, 42(17 suppl): LBA8511., articleTitle=null, refAbstract=null), Reference(id=1326652886177657719, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[72], rfOrder=71, authorNames=null, journalName=null, refType=null, unstructuredReference=WU YL, YANG JC, KIM DW,
et al. PhaseⅡ study of crizotinib in East Asian patients with ROS1-positive advanced non-small-cell lung cancer[J]. J Clin Oncol, 2018,36(14): 1405-1411., articleTitle=null, refAbstract=null), Reference(id=1326652886265738104, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[73], rfOrder=72, authorNames=null, journalName=null, refType=null, unstructuredReference=DRILON A, CHIU CH, FAN Y,
et al. Long-term efficacy and safety of entrectinib in
ROS1 fusion-positive NSCLC[J]. JTO Clin Res Rep, 2022, 3(6): 100332., articleTitle=null, refAbstract=null), Reference(id=1326652886324458361, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[74], rfOrder=73, authorNames=null, journalName=null, refType=null, unstructuredReference=DRILON A, CAMIDGE DR, LIN JJ,
et al. Repotrectinib in
ROS1 fusion-positive non-small-cell lung cancer[J]. N Engl J Med, 2024, 390(2): 118-131., articleTitle=null, refAbstract=null), Reference(id=1326652886391567226, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[75], rfOrder=74, authorNames=null, journalName=null, refType=null, unstructuredReference=LI W, XIONG AW, YANG N,
et al. Efficacy and safety of taletrectinib in patients with advanced or metastatic ROS1+ non-small cell lung cancer: the phase 2 TRUST-I study[J]. J Clin Oncol, 2024, 42(16 suppl): 8520., articleTitle=null, refAbstract=null), Reference(id=1326652886462870395, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[76], rfOrder=75, authorNames=null, journalName=null, refType=null, unstructuredReference=LU S, PAN HM, WU L,
et al. Efficacy, safety and pharmacokinetics of unecritinib(TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a phaseⅠ/Ⅱ trial[J]. Signal Transduct Target Ther, 2023,8(1): 249., articleTitle=null, refAbstract=null), Reference(id=1326652886517396348, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[77], rfOrder=76, authorNames=null, journalName=null, refType=null, unstructuredReference=GAINOR JF, SHAW AT. Novel targets in non-small cell lung cancer:
ROS1 and
RET fusions[J]. Oncologist, 2013,18(7): 865-875., articleTitle=null, refAbstract=null), Reference(id=1326652886588699517, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[78], rfOrder=77, authorNames=null, journalName=null, refType=null, unstructuredReference=AHN BC, KIM YJ, KIM DW,
et al. Lorlatinib in TKI naive, advanced ROS1-positive non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 trial[J]. J Clin Oncol, 2024, 42(16 suppl): 8519., articleTitle=null, refAbstract=null), Reference(id=1326652886685168510, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[79], rfOrder=78, authorNames=null, journalName=null, refType=null, unstructuredReference=LU S, YU Y, GUO Q,
et al. OA21.03 A phase 3b study of 1L savolitinib in patients with locally advanced or metastatic NSCLC harboring
MET exon 14 mutation[J]. J Thorac Oncol, 2023, 18(11): S92-S93., articleTitle=null, refAbstract=null), Reference(id=1326652886760665983, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[80], rfOrder=79, authorNames=null, journalName=null, refType=null, unstructuredReference=MAZIERES J, PAIK PK, GARASSINO MC,
et al. Tepotinib treatment in patients with
MET exon 14-skipping non-small cell lung cancer: long-term follow-up of the VISION phase 2 nonrandomized clinical trial[J]. J Am Med Assoc Oncol, 2023, 9(9): 1260-1266., articleTitle=null, refAbstract=null), Reference(id=1326652886840357760, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[81], rfOrder=80, authorNames=null, journalName=null, refType=null, unstructuredReference=YANG JJ, ZHANG Y, WU L,
et al. 1379P Preliminary results of phase Ⅱ KUNPENG study of vebreltinib in patients(PTS) with advanced NSCLC harboring c-MET alterations[J]. Ann Oncol, 2023, 34(supplement 2): S791., articleTitle=null, refAbstract=null), Reference(id=1326652886920049537, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[82], rfOrder=81, authorNames=null, journalName=null, refType=null, unstructuredReference=YU YF, ZHOU JY, LI XY,
et al. Gumarontinib in patients with non-small-cell lung cancer harbouring
MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial[J]. EClinicalMedicine, 2023, 59: 101952., articleTitle=null, refAbstract=null), Reference(id=1326652887020712834, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[83], rfOrder=82, authorNames=null, journalName=null, refType=null, unstructuredReference=LU S, FANG J, LI XY,
et al. Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring
MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study[J]. Lancet Respir Med, 2021, 9(10):1154-1164., articleTitle=null, refAbstract=null), Reference(id=1326652887112987523, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[84], rfOrder=83, authorNames=null, journalName=null, refType=null, unstructuredReference=WOLF J, SETO T, HAN JY,
et al. Capmatinib in
MET exon 14-mutated or
MET-amplified non-small-cell lung cancer[J]. N Engl J Med, 2020, 383(10): 944-957., articleTitle=null, refAbstract=null), Reference(id=1326652887192679300, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[85], rfOrder=84, authorNames=null, journalName=null, refType=null, unstructuredReference=GRIESINGER F, CURIGLIANO G, THOMAS M,
et al. Safety and efficacy of pralsetinib in
RET fusion-positive non-small-cell lung cancer including as first-line therapy:update from the ARROW trial[J]. Ann Oncol, 2022,33(11): 1168-1178., articleTitle=null, refAbstract=null), Reference(id=1326652887272371077, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[86], rfOrder=85, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHOU CC, SOLOMON B, LOONG HH,
et al. First-line selpercatinib or chemotherapy and pembrolizumab in
RET fusion-positive NSCLC[J]. N Engl J Med, 2023, 389(20):1839-1850., articleTitle=null, refAbstract=null), Reference(id=1326652887339479942, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[87], rfOrder=86, authorNames=null, journalName=null, refType=null, unstructuredReference=PLANCHARD D, SMIT EF, GROEN HJM,
et al. Dabrafenib plus trametinib in patients with previously untreated
BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial[J]. Lancet Oncol, 2017, 18(10): 1307-1316., articleTitle=null, refAbstract=null), Reference(id=1326652887402394503, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[88], rfOrder=87, authorNames=null, journalName=null, refType=null, unstructuredReference=RIELY GJ, SMIT EF, AHN MJ,
et al. PhaseⅡ, open-label study of encorafenib plus binimetinib in patients with
BRAFV600-mutant metastatic non-small-cell lung cancer[J]. J Clin Oncol, 2023, 41(21): 3700-3711., articleTitle=null, refAbstract=null), Reference(id=1326652887473697672, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[89], rfOrder=88, authorNames=null, journalName=null, refType=null, unstructuredReference=DOEBELE RC, DRILON A, PAZ-ARES L,
et al. Entrectinib in patients with advanced or metastatic
NTRK fusion-positive solid tumours: integrated analysis of three phase 1—2 trials[J]. Lancet Oncol, 2020, 21(2): 271-282., articleTitle=null, refAbstract=null), Reference(id=1326652887536612233, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[90], rfOrder=89, authorNames=null, journalName=null, refType=null, unstructuredReference=DRILON A, TAN DSW, LASSEN UN,
et al. Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase fusion-positive lung cancers[J]. JCO Precision Oncology, 2022, 6: e2100418., articleTitle=null, refAbstract=null), Reference(id=1326652887603721098, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[91], rfOrder=90, authorNames=null, journalName=null, refType=null, unstructuredReference=SOLOMON BJ, DRILON A, LIN JJ,
et al. 1372P Repotrectinib in patients(PTS) with
NTRK fusion-positive(NTRK+) advanced solid tumors, including NSCLC:update from the phaseⅠ/Ⅱ TRIDENT-1 trial[J]. Ann Oncol, 2023, 34: S787-S788., articleTitle=null, refAbstract=null), Reference(id=1326652887695995787, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[92], rfOrder=91, authorNames=null, journalName=null, refType=null, unstructuredReference=HEYMACH J, OPDAM F, BARVE MA,
et al. PhaseⅠa/Ⅰb trial of zongertinib(BI 1810631), a HER2-specific tyrosine kinase inhibitor(TKI), in patients(PTS)with HER2 aberration-positive solid tumors: Updated phaseⅠa data from Beamion LUNG-1, including progression-free survival(PFS) data[J]. J Clin Oncol, 2024, 42(16 suppl): 8514., articleTitle=null, refAbstract=null), Reference(id=1326652887758910348, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[93], rfOrder=92, authorNames=null, journalName=null, refType=null, unstructuredReference=GIRARD N, KIM TM, KIM HR,
et al. Safety and anti-tumor activity of BAY 2927088 in patients with
HER2-mutant NSCLC: Results from an expansion cohort of the SOHO-01 phase Ⅰ/Ⅱ study[J]. J Clin Oncol, 2024,42(17 suppl): LBA8598., articleTitle=null, refAbstract=null), Reference(id=1326652887821824909, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[94], rfOrder=93, authorNames=null, journalName=null, refType=null, unstructuredReference=CHAU CH, STEEG PS, FIGG WD. Antibody-drug conjugates for cancer[J]. Lancet, 2019, 394(10200): 793-804., articleTitle=null, refAbstract=null), Reference(id=1326652887901516686, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[95], rfOrder=94, authorNames=null, journalName=null, refType=null, unstructuredReference=AHN MJ, TANAKA K, PAZ-ARES L,
et al. Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phaseⅢ TROPION-Lung01 study[J]. J Clin Oncol, 2024, 43(3): 260-272., articleTitle=null, refAbstract=null), Reference(id=1326652888006374287, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[96], rfOrder=95, authorNames=null, journalName=null, refType=null, unstructuredReference=PLANCHARD D, COZIC N, WISLEZ M,
et al. ICARUS-LUNG01: A phase 2 study of datopotomab deruxtecan(Dato-DXd) in patients with previously treated advanced non-small cell lung cancer(NSCLC), with sequential tissue biopsies and biomarkers analysis to predict treatment outcome[J]. J Clin Oncol, 2024, 42(16 suppl): 8501., articleTitle=null, refAbstract=null), Reference(id=1326652888077677456, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[97], rfOrder=96, authorNames=null, journalName=null, refType=null, unstructuredReference=PAZ-ARES L, AHN MJ, LISBERG AE,
et al. 1314MO TROPION-Lung05: Datopotamab deruxtecan(Dato-DXd)in previously treated non-small cell lung cancer(NSCLC)with actionable genomic alterations(AGAs)[J]. Ann Oncol, 2023, 34(supplement 2): S755-S756., articleTitle=null, refAbstract=null), Reference(id=1326652888157369233, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[98], rfOrder=97, authorNames=null, journalName=null, refType=null, unstructuredReference=PAZ-ARES LG, JUAN-VIDAL O, MOUNTZIOS GS,
et al. Sacituzumab govitecan versus docetaxel for previously treated advanced or metastatic non cmall cell lung cancer:the randomized, open-label phaseⅢ EVOKE-01 study[J].J、 Clin Oncol, 42(24): 2860-2872., articleTitle=null, refAbstract=null), Reference(id=1326652888228672402, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[99], rfOrder=98, authorNames=null, journalName=null, refType=null, unstructuredReference=FANG W, CHENG Y, CHEN ZD,
et al. Abstract CT247:Updated efficacy and safety of anti-TROP2 ADC SKB264(MK-2870) for previously treated advanced NSCLC in phase 2 study[J]. Cancer Res, 2024, 84(7 supplement): CT247., articleTitle=null, refAbstract=null), Reference(id=1326652888299975571, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[100], rfOrder=99, authorNames=null, journalName=null, refType=null, unstructuredReference=GOTO Y, SU WC, LEVY BP,
et al. TROPION-Lung02: Datopotamab deruxtecan(Dato-DXd) plus pembrolizumab(pembro) with or without platinum chemotherapy(Pt-CT) in advanced non-small cell lung cancer (aNSCLC)[J]. J Clin Oncol, 2023, 41(16 suppl):9004., articleTitle=null, refAbstract=null), Reference(id=1326652888367084436, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[101], rfOrder=100, authorNames=null, journalName=null, refType=null, unstructuredReference=FANG WF, WANG QM, CHENG Y,
et al. Sacituzumab tirumotecan(SKB264/MK-2870) in combination with KL-A167(anti-PD-L1) as first-line treatment for patients with advanced NSCLC from the phaseⅡ OptiTROP-Lung01 study[J]. J Clin Oncol, 2024, 42(16 suppl): 8502., articleTitle=null, refAbstract=null), Reference(id=1326652888429998997, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[102], rfOrder=101, authorNames=null, journalName=null, refType=null, unstructuredReference=GOTO K, GOTO Y, KUBO T,
et al. Trastuzumab deruxtecan in patients with
HER2-mutant metastatic non67(anti-PD-L1) as fier: primary results from the randomized, phaseⅡ DESTINY-Lung02 trial[J]. J Clin Oncol, 2023, 41(31):4852-4863., articleTitle=null, refAbstract=null), Reference(id=1326652888497107862, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[103], rfOrder=102, authorNames=null, journalName=null, refType=null, unstructuredReference=LI ZM, SONG ZB, HONG W,
et al. SHR-A1811(antibody-drug conjugate) in advanced
HER2-mutant non-small cell lung cancer: a multicenter, open-label, phase 1/2 study[J]. Signal Transduct Target Ther, 2024, 9(1): 182., articleTitle=null, refAbstract=null), Reference(id=1326652888568411031, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[104], rfOrder=103, authorNames=null, journalName=null, refType=null, unstructuredReference=YU HA, BAIK C, KIM DW,
et al. Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan(HER3-DXd) in
EGFR-mutated NSCLC[J]. Ann Oncol, 2024, 35(5): 437-447., articleTitle=null, refAbstract=null), Reference(id=1326652890241938328, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[105], rfOrder=104, authorNames=null, journalName=null, refType=null, unstructuredReference=YU HA, GOTO Y, HAYASHI H,
et al. HERTHENA-Lung01, a phase Ⅱ trial of patritumab deruxtecan(HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy[J]. J Clin Oncol, 2023, 41(35): 5363-5375., articleTitle=null, refAbstract=null), Reference(id=1326652890338407321, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[106], rfOrder=105, authorNames=null, journalName=null, refType=null, unstructuredReference=CAMIDGE DR, BAR J, HORINOUCHI H,
et al. Telisotuzumab vedotin monotherapy in patients with previously treated c-Metidermal growth factor receptor-mutated type advanced NSCLC: primary analysis of the LUMINOSITY trial[J]. J Clin Oncol, 2024, 42(16 suppl):103., articleTitle=null, refAbstract=null), Reference(id=1326652890460042138, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[107], rfOrder=106, authorNames=null, journalName=null, refType=null, unstructuredReference=CAMIDGE DR, BARLESI F, GOLDMAN JW,
et al. Phase Ⅰb study of telisotuzumab vedotin in combination with erlotinib in patients with c-Met protein-expressing non-small-cell lung cancer[J]. J Clin Oncol, 2023, 41(5): 1105-1115., articleTitle=null, refAbstract=null)], funds=[Fund(id=1326652877910684462, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, awardId=82030045; 82202924, language=CN, fundingSource=国家自然科学基金资助项目(82030045; 82202924), fundOrder=null, country=null)], companyList=[AuthorCompany(id=1326652874844648208, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, xref=null, ext=[AuthorCompanyExt(id=1326652874853036817, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, companyId=1326652874844648208, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China), AuthorCompanyExt(id=1326652874865619730, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652873959650059, companyId=1326652874844648208, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=上海交通大学医学院附属胸科医院肿瘤科,上海 200030)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li {
margin-right: 18px;
}
@media (max-width: 1442px) {
.style-1 .main-menu ul>li a {
font-size: 16px;
padding: 10px 0;
}
}, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li {
margin-right: 18px;
}
@media (max-width: 1442px) {
.style-1 .main-menu ul>li a {
font-size: 16px;
padding: 10px 0;
}
}, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2025.02.001, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2025.02.001, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2025.02.001, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2025.02.001, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1739116800000, fullTextJson=null, articleText=null, reference=null)